N/A N=296 Daily Checklists and Outcome in the Intensive Care Unit
Critical Illness
Primary: Empiric Antibiotic Duration — 3; 3 days — p=0.27
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=99 Black Education and Treatment of Hypertension (BEAT HTN)
Hypertension
Primary: Percentage of Subjects Achieving Blood Pressure Goals — 81; 57 percentage of participants
Phase 2 N=187 Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving
Smoking · Smoking Cessation
Primary: Mean Change From Baseline in Nicotine Cravings VAS Scores in Light Smokers — -15.40; -8.17; -24.42; -17.26 Score on a scale — p=0.0643
N/A N=45 Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Changes of Central Retinal Thickness — 510.35; 468.22; 291.48; 233.33 micrometer — p=0.60
Phase 3 N=1,735 Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission
Disease Transmission, Vertical · Vertical Human Immunodeficiency Virus Transmission · HIV Infections
Primary: Infant HIV Infection Status — 24; 11; 12 participants — p=.046
Phase 3 N=811 A Study in Painful Diabetic Neuropathy
Diabetic Neuropathy, Painful
Primary: Change From Week 8 to Week 16 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form — -2.353; -2.161 units on a scale — p=0.370
Phase 2 N=123 Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths
Hepatitis B
Primary: Qualitative Seroresponsiveness to Hepatitis B Surface Antigen — 41; 52; 6; 3 Participants — p=0.2954
N/A N=16 Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising
Ecchymosis
Primary: Average Bruise Change — -3.68; -3.71; -3.88; -4.13 Units on a Scale
Phase 4 N=36 Aspirin Responsiveness in Women at Risk for Cardiac Events
Heart Disease
Primary: Number of Women Aspirin Resistant — 3 participants
Phase 2 N=38 Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
Multiple Sclerosis
Primary: Number of Participants With Any Adverse Event — 8; 10; 7; 3 participants
Phase 3 N=2,710 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
Colon Adenocarcinoma · Stage IIA Colon Cancer AJCC v7 · Stage IIB Colon Cancer AJCC v7
Primary: Disease-free Survival — 75.5; 77.4 percentage of patients
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
Phase 2 N=102 Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants
Phase 4 N=402 Perioperative Insulin Glargine Dosing Study
Diabetes · Surgery
Primary: Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery — 58.6; 72.4; 74.1; 58.7 Percentage of subjects — p=0.332
Phase 3 N=39 The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
Major Depression · Bipolar Depression · Schizoaffective Disorder
Primary: Number of Side Effects — 19; 13 Number of reported side effects